Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration

NCT00764738 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

91

Enrollment

OTHER

Sponsor class

Conditions

Neovascular Age Related Macular Degeneration

Interventions

DEVICE: OCT, Multifocal ERG, Microperimetry
DRUG: Ranibizumab Ophthalmic

Sponsor

Retina Macula Institute